Denali Receives Formal Letter Regarding FDA Hold On Alzheimer's Potential Program - Denali Therapeutics (

As previously announced, Denali Therapeutics Inc (NASDAQ:DNLI) was informed via e-mail communication from the FDA that DNL919 (ATV:TREM2) Investigational New Drug (IND) application was placed on clinical hold.

Denali has now received a formal clinical hold letter and is moving forward to address the FDA's observations related to the preclinical toxicology assessment.
The Company will also provide the information requested to initiate clinical studies, including proposed changes to the clinical trial protocol, the informed consent form, and the investigator brochure.
Related: FDA Places Clinical Hold On Denali's Alzheimer's Potential Program.
Denali intends to update once a clear path forward has been established.
Price Action: DNLI shares are down 3.99% at $33.46 during the premarket session on Monday's last check.

DNLIDenali Therapeutics Inc

$20.57-%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.